{"id":"NCT00163215","sponsor":"Pfizer","briefTitle":"Growth Retardation In Children With Special Pathological Conditions Or Disease","officialTitle":"Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2005-09-13","resultsPosted":"2012-12-19","lastUpdate":"2012-12-19"},"enrollment":46,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Endocrine System Diseases"],"interventions":[{"type":"DRUG","name":"Somatropin","otherNames":[]}],"arms":[{"label":"Somatropin","type":"EXPERIMENTAL"}],"summary":"To show an increase in annual growth rate 3 years after Visit 2. Annual growth rate in standard deviation (SD) after 3 years will be compared to growth rate before the start of GH treatment.","primaryOutcome":{"measure":"Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population","timeFrame":"Baseline, Month 36","effectByArm":[{"arm":"Genotonorm","deltaMin":-1.29,"sd":1.79}],"pValues":[]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":18,"countries":["France"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281269&StudyName=Growth%20Retardation%20In%20Children%20With%20Special%20Pathological%20Conditions%20Or%20Disease%20"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":46},"commonTop":["Headache","Diarrhoea","Oral herpes","Bronchopulmonary aspergillosis allergic","Influenza"]}}